The specificities of small molecule inhibitors of the TGF beta and BMP pathways

Janis Vogt, Ryan Traynor, Gopal P. Sapkota (Lead / Corresponding author)

    Research output: Contribution to journalArticle

    153 Citations (Scopus)
    674 Downloads (Pure)

    Abstract

    Small molecule inhibitors of type 1 receptor serine threonine kinases (ALKs1-7), the mediators of TGF beta and BMP signals, have been employed extensively to assess their physiological roles in cells and organisms. While all of these inhibitors have been reported as "selective" inhibitors of specific ALKs, extensive specificity tests against a wide array of protein kinases have not been performed. In this study, we examine the specificities and potencies of the most frequently used small molecule inhibitors of the TGF beta pathway (SB-431542, SB-505124, LY-364947 and A-83-01) and the BMP pathway (Dorsomorphin and LDN-193189) against a panel of up to 123 protein kinases covering a broad spectrum of the human kinome. We demonstrate that the inhibitors of the TGF beta pathway are relatively more selective than the inhibitors of the BMP pathway. Based on our specificity and potency profile and published data, we recommend SB-505124 as the most suitable molecule for use as an inhibitor of ALKs 4,5 and 7 and the TGF beta pathway. We do not recommend Dorsomorphin, also called Compound C, for use as an inhibitor of the BMP pathway. Although LDN-193189, a Dorsomorphin derivative, is a very potent inhibitor of ALK2/3 and the BMP-pathway, we found that it potently inhibited a number of other protein kinases at concentrations sufficient to inhibit ALK2/3 and its use as a selective BMP-pathway inhibitor has to be considered cautiously. Our observations have highlighted the need for caution when using these small molecule inhibitors to assess the physiological roles of BMP and TGF beta pathways. (C) 2011 Elsevier Inc. All rights reserved.

    NOTICE: this is the author’s version of a work that was accepted for publication in Cellular Signalling. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Cellular Signalling, [VOL 23, ISSUE 11, (2011)] DOI 10.1016/j.cellsig.2011.06.019

    Original languageEnglish
    Pages (from-to)1831-1842
    Number of pages12
    JournalCellular Signalling
    Volume23
    Issue number11
    DOIs
    Publication statusPublished - Nov 2011

    Cite this

    @article{8fff5a074e6d4f5f83a5f5d8af4fd2a3,
    title = "The specificities of small molecule inhibitors of the TGF beta and BMP pathways",
    abstract = "Small molecule inhibitors of type 1 receptor serine threonine kinases (ALKs1-7), the mediators of TGF beta and BMP signals, have been employed extensively to assess their physiological roles in cells and organisms. While all of these inhibitors have been reported as {"}selective{"} inhibitors of specific ALKs, extensive specificity tests against a wide array of protein kinases have not been performed. In this study, we examine the specificities and potencies of the most frequently used small molecule inhibitors of the TGF beta pathway (SB-431542, SB-505124, LY-364947 and A-83-01) and the BMP pathway (Dorsomorphin and LDN-193189) against a panel of up to 123 protein kinases covering a broad spectrum of the human kinome. We demonstrate that the inhibitors of the TGF beta pathway are relatively more selective than the inhibitors of the BMP pathway. Based on our specificity and potency profile and published data, we recommend SB-505124 as the most suitable molecule for use as an inhibitor of ALKs 4,5 and 7 and the TGF beta pathway. We do not recommend Dorsomorphin, also called Compound C, for use as an inhibitor of the BMP pathway. Although LDN-193189, a Dorsomorphin derivative, is a very potent inhibitor of ALK2/3 and the BMP-pathway, we found that it potently inhibited a number of other protein kinases at concentrations sufficient to inhibit ALK2/3 and its use as a selective BMP-pathway inhibitor has to be considered cautiously. Our observations have highlighted the need for caution when using these small molecule inhibitors to assess the physiological roles of BMP and TGF beta pathways. (C) 2011 Elsevier Inc. All rights reserved. NOTICE: this is the author’s version of a work that was accepted for publication in Cellular Signalling. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Cellular Signalling, [VOL 23, ISSUE 11, (2011)] DOI 10.1016/j.cellsig.2011.06.019",
    author = "Janis Vogt and Ryan Traynor and Sapkota, {Gopal P.}",
    year = "2011",
    month = "11",
    doi = "10.1016/j.cellsig.2011.06.019",
    language = "English",
    volume = "23",
    pages = "1831--1842",
    journal = "Cellular Signalling",
    issn = "0898-6568",
    publisher = "Elsevier",
    number = "11",

    }

    The specificities of small molecule inhibitors of the TGF beta and BMP pathways. / Vogt, Janis; Traynor, Ryan; Sapkota, Gopal P. (Lead / Corresponding author).

    In: Cellular Signalling, Vol. 23, No. 11, 11.2011, p. 1831-1842.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - The specificities of small molecule inhibitors of the TGF beta and BMP pathways

    AU - Vogt, Janis

    AU - Traynor, Ryan

    AU - Sapkota, Gopal P.

    PY - 2011/11

    Y1 - 2011/11

    N2 - Small molecule inhibitors of type 1 receptor serine threonine kinases (ALKs1-7), the mediators of TGF beta and BMP signals, have been employed extensively to assess their physiological roles in cells and organisms. While all of these inhibitors have been reported as "selective" inhibitors of specific ALKs, extensive specificity tests against a wide array of protein kinases have not been performed. In this study, we examine the specificities and potencies of the most frequently used small molecule inhibitors of the TGF beta pathway (SB-431542, SB-505124, LY-364947 and A-83-01) and the BMP pathway (Dorsomorphin and LDN-193189) against a panel of up to 123 protein kinases covering a broad spectrum of the human kinome. We demonstrate that the inhibitors of the TGF beta pathway are relatively more selective than the inhibitors of the BMP pathway. Based on our specificity and potency profile and published data, we recommend SB-505124 as the most suitable molecule for use as an inhibitor of ALKs 4,5 and 7 and the TGF beta pathway. We do not recommend Dorsomorphin, also called Compound C, for use as an inhibitor of the BMP pathway. Although LDN-193189, a Dorsomorphin derivative, is a very potent inhibitor of ALK2/3 and the BMP-pathway, we found that it potently inhibited a number of other protein kinases at concentrations sufficient to inhibit ALK2/3 and its use as a selective BMP-pathway inhibitor has to be considered cautiously. Our observations have highlighted the need for caution when using these small molecule inhibitors to assess the physiological roles of BMP and TGF beta pathways. (C) 2011 Elsevier Inc. All rights reserved. NOTICE: this is the author’s version of a work that was accepted for publication in Cellular Signalling. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Cellular Signalling, [VOL 23, ISSUE 11, (2011)] DOI 10.1016/j.cellsig.2011.06.019

    AB - Small molecule inhibitors of type 1 receptor serine threonine kinases (ALKs1-7), the mediators of TGF beta and BMP signals, have been employed extensively to assess their physiological roles in cells and organisms. While all of these inhibitors have been reported as "selective" inhibitors of specific ALKs, extensive specificity tests against a wide array of protein kinases have not been performed. In this study, we examine the specificities and potencies of the most frequently used small molecule inhibitors of the TGF beta pathway (SB-431542, SB-505124, LY-364947 and A-83-01) and the BMP pathway (Dorsomorphin and LDN-193189) against a panel of up to 123 protein kinases covering a broad spectrum of the human kinome. We demonstrate that the inhibitors of the TGF beta pathway are relatively more selective than the inhibitors of the BMP pathway. Based on our specificity and potency profile and published data, we recommend SB-505124 as the most suitable molecule for use as an inhibitor of ALKs 4,5 and 7 and the TGF beta pathway. We do not recommend Dorsomorphin, also called Compound C, for use as an inhibitor of the BMP pathway. Although LDN-193189, a Dorsomorphin derivative, is a very potent inhibitor of ALK2/3 and the BMP-pathway, we found that it potently inhibited a number of other protein kinases at concentrations sufficient to inhibit ALK2/3 and its use as a selective BMP-pathway inhibitor has to be considered cautiously. Our observations have highlighted the need for caution when using these small molecule inhibitors to assess the physiological roles of BMP and TGF beta pathways. (C) 2011 Elsevier Inc. All rights reserved. NOTICE: this is the author’s version of a work that was accepted for publication in Cellular Signalling. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Cellular Signalling, [VOL 23, ISSUE 11, (2011)] DOI 10.1016/j.cellsig.2011.06.019

    UR - http://www.scopus.com/inward/record.url?scp=80051471864&partnerID=8YFLogxK

    U2 - 10.1016/j.cellsig.2011.06.019

    DO - 10.1016/j.cellsig.2011.06.019

    M3 - Article

    VL - 23

    SP - 1831

    EP - 1842

    JO - Cellular Signalling

    JF - Cellular Signalling

    SN - 0898-6568

    IS - 11

    ER -